Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.juro.2007.01.172 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Registry versus claims-based index dates for studies of cancer diagnosis in administrative data.
Cancer Causes Control
January 2025
Department of Epidemiology, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Purpose: Studies of healthcare encounters leading to cancer diagnosis have increased over recent years. While some studies examine healthcare utilization before the cancer registry date of diagnosis, relevant pre-diagnosis interactions are not always immediately prior to this date due to date abstraction guidelines. We evaluated agreement of a registry date with a claims-based index and examined Emergency Department (ED) involvement in cancer diagnosis as an example of possible pre-diagnostic healthcare misclassification that could arise from improper date choice.
View Article and Find Full Text PDFEvolving Paradigms in Prostate Cancer: The Integral Role of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging and Therapeutic Decision-Making.
Int J Radiat Oncol Biol Phys
February 2025
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Prostate-specific membrane antigen (PSMA) positron emission tomography or computed tomography (PET/CT) has emerged as a superior imaging option to conventional imaging for prostate cancer. The majority of early evidence and prospective trials evaluated PSMA PET/CT in the biochemical recurrence or metastatic setting. However, there has been an increasing number of prospective trials in the primary setting.
View Article and Find Full Text PDFAdiposity assessed close to diagnosis and prostate cancer prognosis in the EPIC study.
JNCI Cancer Spectr
September 2024
Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK.
Article Synopsis
- Being overweight (adiposity) can increase the risk of dying from prostate cancer and other causes in men who have this disease.
- A study followed 1968 men for about 9.5 years and found that gaining weight around the time of being diagnosed with prostate cancer made it more likely for them to not survive as long.
- The results suggest that men should try to keep a healthy weight to potentially live longer, especially after being diagnosed with prostate cancer, but more research is needed to fully understand the connection.
Quality of life assessment among ethnically diverse Black prostate cancer survivors: a constructivist grounded theory approach.
J Cancer Surviv
May 2024
Prevention, Symptom Control and Survivorship, and Care Delivery Transformation (CPSD) Program, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL, USA.
Purpose: Prostate cancer (CaP) is the most common cancer in Black men (BM), and the number of Black CaP survivors is rapidly increasing. Although Black immigrants are among the fastest-growing and most heterogeneous ethnic groups in the USA, limited data exist regarding their CaP experiences. Therefore, this study aimed to explore and model the experiences of ethnically diverse Black men with CaP.
View Article and Find Full Text PDFAssociation of Baseline Pre-Diagnosis and Post-Diagnosis Obesity and Weight Change with Cardiovascular Risk and Survival Among Nonmetastatic Prostate Cancer Survivors.
Clin Genitourin Cancer
June 2024
Huntsman Cancer Institute, Salt Lake City, UT. Electronic address:
Introduction: Obesity in prostate cancer survivors may increase mortality. Better characterization of this effect may allow better counseling on obesity as a targetable lifestyle factor to reduce mortality in prostate cancer survivors. The purpose of this study was to determine whether pre- and post-diagnostic obesity and weight change affect all-cause mortality, cardiovascular disease specific mortality, and prostate cancer specific mortality in patients with nonmetastatic prostate cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!